Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers
The Breast · 2023
DOI: 10.1016/j.breast.2023.06.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Breast, 2023. Verfasst von Melanie Machiels und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Iridium Netwerk, University of Antwerp, Health & Sciences, Antwerp, Belgium. Electronic address: Melanie.Machiels@g…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Breast Cancer Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to de-escalate or omit RT based on clinicopathologic features have been successful, there remain substantial opportunities to refine individualised RT based on tumour biology. A major area of clinical and research interest is to ascertain the individualised risk of loco-regional recurrence to direct treatment decisions regarding escalation and de-escalation of RT. Patient-tailored treatment with RT is considerably lagging behind compared with the massive progress made in the field of personalised medicine that currently mainly applies to decisions on the use of systemic therapy or targeted agents. Herein we review select literature surrounding the use of tumour genomic biomarkers and biomarkers of the immune system, including tumour infiltrating lymphocytes (TILs), within the management of breast cancer, specifically as they relate to progress in moving toward analytically validated and clinically tested biomarkers utilized in RT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Iridium Netwerk, University of Antwerp, Health & Sciences, Antwerp, Belgium. Electronic address: Melanie.Machiels@gza.be.
- Department of Radiation Oncology, Iridium Netwerk, University of Antwerp, Health & Sciences, Antwerp, Belgium.
- Department of Pathology, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Departments of Radiation Oncology, Pathology & Laboratory Medicine, And Cancer Biology, The University of Kansas Medical Center, KS, USA.
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, Breast Unit, The Royal Marsden NHS Foundation Trust, UK.
- Université Libre de Bruxelles (ULB), Hôpitaux Universitaires de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium.
Förderung
- Breast Cancer Research Foundation
Zitieren
APA
Machiels, M., Oulkadi, R., Tramm, T., Stecklein, S. R., Somaiah, N., De Caluwé, A., Klein, J., Tran, W. T., & Salgado, R. (2023). Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers. The Breast. https://doi.org/10.1016/j.breast.2023.06.010
Vancouver
Machiels M, Oulkadi R, Tramm T, Stecklein SR, Somaiah N, De Caluwé A, et al. Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers. The Breast. 2023. doi:10.1016/j.breast.2023.06.010
BibTeX
@article{Machiels2023,
author = {Machiels, Melanie and Oulkadi, Redouane and Tramm, Trine and Stecklein, Shane R and Somaiah, Navita and De Caluwé, Alex and Klein, Jonathan and Tran, William T and Salgado, Roberto},
title = {Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers},
journal = {The Breast},
year = {2023},
doi = {10.1016/j.breast.2023.06.010}
}
EUVIMED